Most Read Articles
01 Oct 2015
BLACKMORES VITAMIN D3 – Vitamin D3 1,000 IU Capsules
15 Dec 2016
New drug applications approved by US FDA as of 1 - 15 December 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Kavitha G. Shekar, 21 Jun 2016

The American Diabetes Association’s (ADA) President Desmond Schatz challenged the scientific community to transform diabetes from an invisible disease to a highly visible crisis. “Diabetes is an epidemic spiralling out of control across this country and around the world, yet it remains largely invisible,” he said, speaking at the 76th Scientific Sessions of ADA in New Orleans, Louisiana, US.

31 Jul 2017
New drug applications approved by US FDA as of 16 - 31 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Metabolic syndrome not associated with knee osteoarthritis

09 May 2017

Metabolic syndrome (MetS) or its components show no relationship with incident knee osteoarthritis (OA), although there may be an association with high blood pressure that requires further investigation, according to the results of the Framingham OA study.

The study included 991 individuals (mean age 54.2 years; 55.1 percent female). OA evaluations were conducted in 1992 to 1995 and in 2002 to 2005, while MetS component assessment was done right after the baseline visit.

Incident radiographic OA (ROA) was defined as having a Kellgren and Lawrence grade ≥2 at follow-up, whereas incident symptomatic OA (SxOA) was described as the development of the new combination of ROA and knee pain.

Binary regression analysis with generalized estimating equations was used to test the association of MetS (according to the Adult Treatment Panel III criteria) and its components with the risk of incident ROA and SxOA before and after adjustment for body mass index (BMI).  

Results showed that 26.7 percent of men and 22.9 percent of women had MetS. Initially, MetS and many of its components were associated with both incident ROA and SxOA. However, these associations were substantially attenuated and became nonsignificant after controlling for BMI and body weight.

Of note, an association between high blood pressure, particularly diastolic pressure, and SxOA persisted in both men and women.

MetS ups the risk of cardiovascular disease and mortality. Its components include central obesity, dyslipidaemia, impaired fasting glucose and hypertension. Several studies have reported an association between central obesity and BMI, which is a well-known risk factor for knee OA. Other mechanisms by which MetS components may influence the occurrence of OA are low-grade inflammation, alteration of the microvasculature of subchondral bone and neuromuscular impairment. [Cardiol Res Pract 2014;2014:21; Curr Opin Rheumatol 2010;22:533-7; Rheumatology (Oxford) 2007;46:1763-8; Ann Rheum Dis 2011;70:1354-6]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2015
BLACKMORES VITAMIN D3 – Vitamin D3 1,000 IU Capsules
15 Dec 2016
New drug applications approved by US FDA as of 1 - 15 December 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Kavitha G. Shekar, 21 Jun 2016

The American Diabetes Association’s (ADA) President Desmond Schatz challenged the scientific community to transform diabetes from an invisible disease to a highly visible crisis. “Diabetes is an epidemic spiralling out of control across this country and around the world, yet it remains largely invisible,” he said, speaking at the 76th Scientific Sessions of ADA in New Orleans, Louisiana, US.

31 Jul 2017
New drug applications approved by US FDA as of 16 - 31 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.